[이데일리 나은경 기자] Ubix Therapeutics announced on the 17th that a research paper on a BTK inhibitor targeting B-cell lymphoma has been published in the online edition of ‘Blood Advance’, an international academic journal published by the American Society of Hematology (ASH).
This study, conducted jointly by Ubic Therapeutics and the Korea Institute of Chemical Technology Research, identified stronger intracellular signaling inhibitory effects than BTK inhibitors, the degradation effects of various mutant proteins resistant to existing inhibitors, and anticancer effects in mouse models. relapsed and refractory patients after conventional drug treatment were suggested.
BTK inhibitor is a substance that degrades Bruton’s kinase (BTK), which plays a central signaling role in hematological malignancies caused by abnormal B cell receptor activation. Anticancer effects have been confirmed in various blood cancer cell lines, including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and chronic myelogenous leukemia (CML). The company explained that the development of the BTK disintegrator is expected to contribute to improving the quality of treatment for drug-resistant hematological cancer patients.
Seo Bo-kwang, CEO of Ubix Therapeutics, said, “We are conducting a non-clinical toxicity test of a new optimized drug candidate based on a proteolytic agent, and we plan to conduct a clinical trial next year.”
|
|
